

Appl. No. 09/177,711
Amdt. dated October 21, 2003
Amendment under 37 CFR 1.116 Expedited Procedure
Examining Group

PATENT

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-59 (canceled)

Claim 60 (currently amended): A method of decreasing pain associated with use of prostaglandins for treatment of erectile tissue dysfunction comprising administering to a human subject in need thereof an effective amount of prostaglandin and at least one NO producing agent at a low dose, which does not produce significant systemic side effects, but which decreases pain associated with prostaglandin use, wherein said low dose of said at least one NO producing agent is a unit dose of about 0.88 μ mole or less, and wherein the administration is therapeutically synergistic in the treatment of erectile tissue dysfunction, and is not an intraurethral administration.

Claim 61 (currently amended): The method of claim 60 wherein the subject human is male.

Claim 62 (currently amended): The method of claim 60 wherein the subject human is female.

Claim 63 (canceled).

Claim 64 (previously presented): The method of claim 60 wherein the NO producing agent inhibits a cyclic nucleotide phosphodiesterase.

Appl. No. 09/177,711
Amdt. dated October 21, 2003
Amendment under 37 CFR 1.116 Expedited Procedure
Examining Group

PATENT

Claim 65 (previously presented): The method of claim 64 wherein the cyclic nucleotide phosphodiesterase is PDE3.

Claim 66 (currently amended): The method of claim 60 wherein the NO producing agent is delivered by a route selected from the group consisting of oral administration, intravenous administration, subcutaneous administration, inhalation or intranasal administration, transdermal application, topical application, rectal administration, intravaginal administration, and intracavemous introduction.

Claim 67 (previously presented): The method of claim 60 wherein two agents are administered.

Claim 68 (previously presented): The method of claim 60 wherein the NO producing agent is selected from the group consisting of glyceryl trinitrate, isosorbide 5-mononitrate, isosorbide dinitrate, pentaerythritol tetranitrate, erythrityl tetranitrate, sodium nitroprusside, 3-morpholinosydnonimine, molsidomine, S-nitroso-N-acetylpenicillamine, S-nitrosoglutathione, N-hydroxy-L-arginine, S,S-dinitrosodithiol and NO gas.

Claim 69 (previously presented): The method of claim 60 wherein the NO producing agent is glyceryl trinitrate.

Claim 70-111 (canceled)

Claim 112 (new): The method of claim 66 wherein the NO producing agent is delivered by inhalation.

Appl. No. 09/177,711
Amdt. dated October 21, 2003
Amendment under 37 CFR 1.116 Expedited Procedure
Examining Group

PATENT

Claim 113 (new): The method of claim 66 wherein the NO producing agent is delivered by transdermal application.

Claim 114 (new): The method of claim 66 wherein the NO producing agent is delivered by oral administration.

Claim 115 (new): The method of claim 60 wherein said NO producing agent augments the action of cGMP.

Claim 116 (new): The method of claim 60 wherein said NO agent is sodium nitroprusside and said effective amount of prostaglandin is an effective amount of prostaglandin E1.

Claim 117 (new): The method of claim 60 wherein said at least one NO producing agent is a unit dose of 200 μ g or less.

Claim 118 (new): The method of claim 60 wherein the mole ratio of said effective amount of prostaglandin to said at least one NO producing agent is about 1 to 12.

Claim 119 (new): The method of claim 60 wherein the mole ratio of said effective amount of prostaglandin to said at least one NO producing agent is about 1 to 4.

Claim 120 (new): The method of claim 60 wherein the mole ratio of said effective amount of prostaglandin to said at least one NO producing agent is about 1 to 3.

Claim 121 (new): The method of claim 116 wherein said sodium nitroprusside administered is about 50 μ g and said effective amount of prostaglandin (PGE1) administered is about 5-20 μ g.

Appl. No. 09/177,711
Amdt. dated October 21, 2003
Amendment under 37 CFR 1.116 Expedited Procedure
Examining Group

PATENT

Claim 122 (new): The method of claim 66 wherein said NO producing agent is delivered by intracavernous administration.